Papillon-Cavanagh et al. investigated the utility of STK11/KEAP1 mutations as predictive biomarkers in patients diagnosed with stage IIIB, IIIC, IVA, or IVB non-squamous NSCLC. Here, KEAP1 is linked to non-small cell lung carcinoma.